The Clinical Utility of Combinatorial Pharmacogenomic Testing for Patients with Depression: A Meta-Analysis
Open Access
- 17 April 2020
- journal article
- review article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 21 (8) , 559-569
Abstract
Aim: To perform a meta-analysis of prospective, two-arm studies examining the clinical utility of using the combinatorial pharmacogenomic test, GeneSight Psychotropic, to inform treatment decisions...Keywords
This publication has 34 references indexed in Scilit:
- Duration of untreated illness and outcomes in unipolar depression: A systematic review and meta-analysisJournal of Affective Disorders, 2014
- Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient settingPharmacogenetics and Genomics, 2013
- Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine DosingClinical Pharmacology & Therapeutics, 2013
- Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depressionTranslational Psychiatry, 2013
- Using a pharmacogenomic algorithm to guide the treatment of depressionTranslational Psychiatry, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- What is “quality of evidence” and why is it important to clinicians?BMJ, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D ReportAmerican Journal of Psychiatry, 2006
- 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*Clinical Pharmacology & Therapeutics, 1998